Examining Lithium's Mechanism in Bipolar Disorder

Официальное название

Investigating the Acute Effect of Lithium on Visual and Non-visual Responses to Light in Healthy Individuals

Обзор

The primary objective of the current study is to examine the acute effect of lithium on the visual and non-visual responses to light in a sample of healthy participants. Our experiments will investigate the effects of lithium on light sensitivity at the level of the retina as well as central visual and non-visual pathways. Our primary hypothesis is that the administration of lithium to healthy volunteers will reduce the magnitude of a range of non-visual responses to light including melatonin suppression, alertness, performance, mood and electrophysiology in a manner that is dependent of the amount of lithium in the brain. To better understand the postulated effects of lithium on light sensitivity and to examine its relationship at the level of the retina, we will assess the visual and non-visual responses to light, as well as the distribution of lithium in the brain using a non-invasive imaging technique. In addition to that, we also aim to examine the impact of both lithium and light on a molecular level through whole blood transcriptome sequencing.

Вмешательства

• Препарат Lithium carbonate (Priadel)
  Oral lithium carbonate 600 mg daily for 7 days prior to the second laboratory assessment (and for both days while in the laboratory)
• Другое Controlled light exposure
  Participants undergo 90-minute dim light (\<1 lux) and light exposure (100-850 lux) conditions during laboratory assessments to evaluate visual and non-visual responses to light.

Первичные конечные точки

• Plasma melatonin change in response to light stimulation [Срок оценки: Measured during the 90-minute light exposure session after 7 days of lithium treatment and after 7 days in the no-lithium condition (days 9-11 and 19-21).]
• Brain lithium signal intensity measured by 7Li-MRI [Срок оценки: Measured once following 9 days of lithium carbonate administration (Day 21)]

Вторичные конечные точки (10)

• Difference in colour vision post-light exposure between lithium and no-lithium conditions [Срок оценки: Measured immediately following the 90-minute light exposure session after 7 days in the lithium condition and after 7 days in the no-lithium condition (days 9-11 and 19-21)]
• Waking EEG Measures [Срок оценки: EEG recordings will occur pre, post and throughout the 90-minute light exposure during days 9-11 and 19-21. EEG recordings will be conducted hourly when the participant is awake in the laboratory.]
• Pittsburgh Sleep Quality Index [Срок оценки: Measured at screening and following 7 days of lithium administration (screening stage 2 and day 19)]
• Munich Chronotype Questionnaire [Срок оценки: Measured at screening and following 7 days of lithium administration (screening Stage 2 and Day 19)]
• General Health Questionnaire - 12 [Срок оценки: Measured at screening and following 7 days of lithium administration (screening stage 2 and day 19).]
• Karolinska Sleepiness Scale [Срок оценки: Measured during and immediately following the 90-minute light exposure session after 7 days in the no-lithium condition and after 7 days of lithium administration (days 9-11 and 19-21).]
• Psychomotor Vigilance Test [Срок оценки: Measured immediately following the 90-minute light exposure session after 7 days in the no-lithium condition and after 7 days of lithium administration. (And hourly while awake in the laboratory) (Days 9-11 and 19-21)]
• Morningness-Eveningness Questionnaire [Срок оценки: Measured at screening and following 7 days of lithium administration (screening stage 2 and day 19).]
• Reading the Mind in the Eyes [Срок оценки: This task will be implemented during the laboratory segment of the lithium and no-lithium condition. The task will be implemented hourly when the participant is awake in the laboratory. (Days 9-11 and Days 19-21)]
• Karolinska Drowsiness Test [Срок оценки: Days 9-11 and 19-21, hourly while awake and before/after the light exposure segments.]

Критерии участия

Критерии включения

• Aged between 18 and 40 years old
• Fluent in English (both spoken and written)
• Sleep duration between 6.5 and 9 hours daily
• Have a regular normal sleep schedule with bedtime (weekdays) between 21:30 and 01:00.
• BMI between 18 and 28kg/m2
• Currently enrolled and registered with a general practitioner
• Female participants only: should use effective contraception or refrain from engaging in sexual activity that could result in pregnancy during participation in the study.

Критерии исключения

• History of psychiatric or neurological disorders
• First-degree family history of psychosis or severe mood disorder
• Current or past suicidal ideation or self-harm
• Current, chronic infections or diseases.
• Life-threatening allergies, specifically a nut allergy.
• Known visual disorders e.g., colour blindness, glaucoma, cataracts, diabetic retinopathy.
• Known medical conditions that could affect the conduct of the study including

• sleep disorders
• cancer
• diabetes
• anaemia
• epilepsy
• psoriasis
• thyroid disorders
• kidney disease
• severe eczema
• anemia
• migraines
• Taking any long-term or regular medications other than oral contraceptives (e.g., antidepressants, diuretics (water-tablets), pain killers or anti-inflammatory drugs (such as ibuprofen) or medications for high blood pressure).
• Have donated blood in the past 1 month
• Regular or recent recreational drug use
• Chronic alcohol addiction/misuse
• Known contraindication to magnetic resonance imaging such as pacemaker or metal implants, recent surgery, severe claustrophobia and/or recent head or neck tattoos.
• A current smoker (including use of cigarettes, vapes, and/or cigars).
• Planning to travel across time zones at any point in time during the conduct of the study or have travelled across time zones within 1 month prior to enrolment.
• Currently work night shifts
• Been a shift worker in the past 3 months.
• Current enrolment in any other interventional studies
• Enrolment in any other interventional studies in the 1 month prior to the start of participation in this study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Фундаментальное исследование

Центры проведения

Великобритания · 1 центр

• Northumbria University — Newcastle upon Tyne

Публикации

• Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C; New Collective Author. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol. 2000 Aug 1;526 Pt 3(Pt 3):695-702. doi: 10.1111/j.1469-7793.2000.00695.x. PMID 10922269
• Merikangas KR, Swendsen J, Hickie IB, Cui L, Shou H, Merikangas AK, Zhang J, Lamers F, Crainiceanu C, Volkow ND, Zipunnikov V. Real-time Mobile Monitoring of the Dynamic Associations Among Motor Activity, Energy, Mood, and Sleep in Adults With Bipolar Disorder. JAMA Psychiatry. 2019 Feb 1;76(2):190-198. doi: 10.1001/jamapsychiatry.2018.3546. PMID 30540352
• Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol. 2001 Dec;21(6):605-16. doi: 10.1023/a:1015187601628. PMID 12043836
• Freedman MS, Lucas RJ, Soni B, von Schantz M, Munoz M, David-Gray Z, Foster R. Regulation of mammalian circadian behavior by non-rod, non-cone, ocular photoreceptors. Science. 1999 Apr 16;284(5413):502-4. doi: 10.1126/science.284.5413.502. PMID 10205061
• Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, Klein T, Rizzo JF 3rd. Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med. 1995 Jan 5;332(1):6-11. doi: 10.1056/NEJM199501053320102. PMID 7990870
• Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Rosenthal NE. Manic-depressive patients may be supersensitive to light. Lancet. 1981 Feb 14;1(8216):383-4. doi: 10.1016/s0140-6736(81)91697-4. No abstract available. PMID 6110011
• Ritter P, Soltmann B, Sauer C, Yakac A, Boekstaegers L, Reichard M, Koenitz K, Bauer M, Guldner H, Neumann S, Wieland F, Skene DJ. Supersensitivity of Patients With Bipolar I Disorder to Light-Induced Phase Delay by Narrow Bandwidth Blue Light. Biol Psychiatry Glob Open Sci. 2021 Jun 19;2(1):28-35. doi: 10.1016/j.bpsgos.2021.06.004. eCollection 2022 Jan. PMID 36324599
• Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013 Feb;27(2):135-53. doi: 10.1007/s40263-013-0039-0. PMID 23371914

Идентификаторы

NCT: NCT07750925 · 333056 · 226787/Z/22/Z

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗